Cargando…
Optimal induction chemotherapeutic regimen followed by concurrent chemotherapy plus intensity-modulated radiotherapy as first-line therapy for locoregionally advanced nasopharyngeal carcinoma
For patients with locoregionally advanced nasopharyngeal carcinoma (NPC), induction chemotherapy (IC) regimens based on TPF (docetaxel, cisplatin, and 5-fluorouracil), TP (docetaxel and cisplatin), and GP (gemcitabine and cisplatin) have shown excellent survival outcomes as the first-line therapy; h...
Autores principales: | Wang, Fangzheng, Chuner, Jiang, Lei, Wang, Fengqin, Yan, Zhimin, Ye, Quanquan, Sun, Tongxin, Liu, Zhenfu, Fu, Yangming, Jiang |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7523833/ https://www.ncbi.nlm.nih.gov/pubmed/32991429 http://dx.doi.org/10.1097/MD.0000000000022283 |
Ejemplares similares
-
Survival without concurrent chemotherapy for locoregionally advanced nasopharyngeal carcinoma treated with induction chemotherapy plus intensity-modulated radiotherapy: Single-center experience from an endemic area
por: Fangzheng, Wang, et al.
Publicado: (2019) -
Influence of concurrent chemotherapy on locoregionally advanced nasopharyngeal carcinoma treated with neoadjuvant chemotherapy plus intensity-modulated radiotherapy: A retrospective matched analysis
por: Wang, Fangzheng, et al.
Publicado: (2020) -
Treatment Outcomes of 257 Patients with Locoregionally Advanced Nasopharyngeal Carcinoma Treated with Nimotuzumab Plus Intensity-Modulated Radiotherapy with or without Chemotherapy: A Single-Institution Experience
por: Wang, Fangzheng, et al.
Publicado: (2017) -
Combined radiotherapy and chemotherapy versus radiotherapy alone in elderly patients with nasopharyngeal carcinoma: A SEER population-based study
por: Lu, Yan, et al.
Publicado: (2021) -
Gemcitabine/cisplatin induction chemotherapy before concurrent chemotherapy and intensity-modulated radiotherapy improves outcomes for locoregionally advanced nasopharyngeal carcinoma
por: Fangzheng, Wang, et al.
Publicado: (2017)